Recombinant ADAMTS13 Effective, Safe in Congenital Thrombotic Thrombocytopenic Purpura
THURSDAY, May 2, 2024-- Prophylaxis with recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura (TTP) leads to ADAMTS13 activity reaching approximately 100 percent of normal levels, according to a study published...